Back to Stakeholders
Research, Drug Development & ManufacturingAcademic & Non-Profit Research
Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchUniversities and Colleges with Dedicated Psychedelic Research Groups
Research, Drug Development & Manufacturing

Columbia University

United States
7 Trials1 Paper

Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.

Academic Research

1 papers

Published Papers

1

Trial Involvement

7

Distinct Focus Topics

0

Latest Publication

Feb 13, 2026

Quick Facts

Type
academic
HQ
United States
Website
Visit

Sponsored Trials

4
RecruitingII

Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication

Start Date
Compounds
Psilocybin
TerminatedI, II

Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics (Keta4SI)

Start Date
Compounds
Ketamine, Placebo
TerminatedI

The Role of HNKs in the Antidepressant Effect of Ketamine

Start Date
Compounds
Ketamine
CompletedII

Ketamine in the Treatment of Depression

Start Date
Compounds
Ketamine, Placebo

Collaborated Trials

3
Not yet recruitingII

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence (PsiPTSD)

Start Date
Compounds
Psilocybin
Not yet recruitingII

PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study (PATSUD)

Start Date
Compounds
Psilocybin
RecruitingI

Treatment of Persistent Post-concussive Symptoms With Psilocybin Assisted Therapy (PatACT)

Start Date
Compounds
Psilocybin

Research Papers

1
Paywallmeta

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

This pooled analysis (s=9) examined how much session facilitators shape participants' acute subjective effects across psilocybin studies involving 298 participants and 60 facilitators, finding that facilitator influence was negligible in healthy volunteers (0.8% of variance) but clinically meaningful in patient samples (13.6%), comparable to or exceeding typical therapist effects seen in conventional psychotherapy.

Published
Journal
Psychiatry Research
Authors
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia-Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., Nayak, S. M.